Moreno-Fernandez J., Chico A., Martínez-Brocca M.A., Beato-Víbora P.I., Vidal M., Piedra M., Quirós C., Muñoz-Rodríguez J.R.. Continuous Subcutaneous Insulin Infusion in Type 1 Diabetes Mellitus Patients: Results from the Spanish National Registry. Diabetes Technology & Therapeutics. 2022; 24(12)DOI:10.1089/dia.2022.0207. PMID:35947087. IF:5.400(Q1/3D).

Casas J.A.V., Sambo M., López C.L., Durán-Poveda M., García J.R.-V., Santos R.J., Llanos M., Navarro-González E., Aller J., Pubul V., Guadalix S., Crespo G., González C., Zafón C., Navarro M., Santamaría-Sandi J., Segura Á., Gajate P., Gómez-Balaguer M., Valdivia J., Puig-Domingo M., Galofré J.C., Castelo B., Villanueva M.J., Argüelles I., Orcajo-Rincón L.. Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study. European Thyroid Journal. 2022; 11(5)DOI:10.1530/ETJ-21-0111. PMID:35900793. IF:4.700(Q2/3D).

Pérez Pérez A., Ortega Martínez de Victoria E., Arrieta Blanco F., Caixàs Pedragós A., Santos Mazo E., Fernández-Catalina P., Martínez-Hervas S., López-Medina J.A., Suárez-Gutiérrez L., Urgeles Planelles J.R., Gatell Menchén S., Tinahones Madueño F.. First clinical and efficacy data on evolocumab in routine clinical practice in endocrinology and nutrition services in Spain: a retrospective observational study (RETOSS-ENDO). Endocrinologia Diabetes y Nutricion. 2022; 69(7)DOI:10.1016/j.endinu.2021.07.009. PMID:35995680. IF:1.900(Q4/9D).

Tomic D., Morton J.I., Chen L., Salim A., Gregg E.W., Pavkov M.E., Arffman M., Balicer R., Baviera M., Boersma-van Dam E., Brinks R., Carstensen B., Chan J.C.N., Cheng Y.J., Fosse-Edorh S., Fuentes S., Gardiner H., Gulseth H.L., Gurevicius R., Ha K.H., Hoyer A., Jermendy G., Kautzky-Willer A., Keskimäki I., Kim D.J., Kiss Z., Klimek P., Leventer-Roberts M., Lin C.-Y., Lopez-Doriga Ruiz P., Luk A.O.Y., Ma S., Mata-Cases M., Mauricio D., McGurnaghan S., Imamura T., Paul S.K., Peeters A., Pildava S., Porath A., Robitaille C., Roncaglioni M.C., Sugiyama T., Wang K.-L., Wild S.H., Yekutiel N., Shaw J.E., Magliano D.J.. Lifetime risk, life expectancy, and years of life lost to type 2 diabetes in 23 high-income jurisdictions: a multinational, population-based study. Lancet Diabetes & Endocrinology. 2022; 10(11)DOI:10.1016/S2213-8587(22)00252-2. PMID:36183736. IF:44.500(Q1/1D).

Puig-Jové, C, Viñals, C, Conget, I, Quirós, C, Vinagre, I, Berrocal, B, Blanco-Carrasco, AJ, Granados, M, Mesa, A, Serés-Noriega, T, Giménez, M, Perea, V, Amor, AJ. Association between the GMI/HbA1c ratio and preclinical carotid atherosclerosis in type 1 diabetes: impact of the fast-glycator phenotype across age groups. Cardiovascular Diabetology. 2025; 24(1)DOI:10.1186/s12933-025-02637-4. PMID:39953520. IF:10.600(Q1/1D).

Gourdy, P, Bonadonna, RC, Mauricio, D, Müller-Wieland, D, Mauquoi, C, Vera, C, Bonnemaire, M, Freemantle, N. Effectiveness and safety of insulin glargine 300 U/mL in insulin-naïve individuals according to diabetes duration: Results from the REALI European pooled data analysis. DIABETES OBESITY & METABOLISM. 2025; 27(1)DOI:10.1111/dom.16008. PMID:39420531. IF:5.700(Q1/2D).

Fernandez-Camins, B, Vlacho, B, Canudas, A, Ortega, M, Granado-Casas, M, Perera-LLuna, A, Boluda-Sanson, A, El-Khattabi-Ofkir, Y, Franch-Nadal, J, Mauricio, D. Characterisation of type 2 diabetes subgroups at diagnosis: the COPERNICAN prospective observational cohort study protocol. BMJ Open. 2024; 14(12)DOI:10.1136/bmjopen-2023-083825. PMID:39675821. IF:2.300(Q2/3D).

Beato-Víbora, PI, Chico, A, Moreno-Fernandez, J, Bellido-Castañeda, V, Nattero-Chávez, L, Picón-César, MJ, Martínez-Brocca, MA, Giménez-Alvarez, M, Aguilera-Hurtado, E, Climent-Biescas, E, Azriel-Mir, S, Rebollo-Román, A, Yoldi-Vergara, C, Pazos-Couselo, M, Alonso-Carril, N, Quirós, C. A Multicenter Prospective Evaluation of the Benefits of Two Advanced Hybrid Closed-Loop Systems in Glucose Control and Patient-Reported Outcomes in a Real-world Setting (vol 47, pg 216, 2024). DIABETES CARE. 2024; 47(12)DOI:10.2337/dc24-er12a. PMID:39265091. IF:16.600(Q1/1D).

Antentas, M, Rojo-López, MI, Vendrell, P, Granado-Casas, M, Genua, I, Fernandez-Camins, B, Rossell, J, Niño-Narvión, J, Moreira, E, Castelblanco, E, Ortega, E, Vlacho, B, Alonso, N, Mauricio, D, Julve, J. Impact of Dietary Niacin on Metabolic Dysfunction-Associated Steatotic Liver Disease in Mediterranean Subjects: A Population-Based Study. Nutrients. 2024; 16(23)DOI:10.3390/nu16234178. PMID:39683571. IF:5.000(Q1/2D).

Hernández-Teixidó, C, de la Puente, JB, Jiménez, SM, Fernández-Camins, B, Mauricio, D, Aroca, PR, Vlacho, B, Franch-Nadal, J. Incidence of Diabetic Retinopathy in Individuals with Type 2 Diabetes: A Study Using Real-World Data. Journal of Clinical Medicine. 2024; 13(23)DOI:10.3390/jcm13237083. PMID:39685542. IF:2.900(Q1/2D).

Magliano, DJ, Chen, L, Morton, J, Salim, A, Carstensen, B, Gregg, EW, Pavkov, ME, Arffman, M, Colhoun, HM, Ha, KH, Imamura, T, Jermendy, G, Kim, DJ, Kiss, Z, Mauricio, D, Mcgurnaghan, SJ, Nishioka, Y, Wild, SH, Winell, K, Shaw, JE. Trends in the incidence of young-adult-onset diabetes by diabetes type: a multi-national population-based study from an international diabetes consortium. Lancet Diabetes & Endocrinology. 2024; 12(12)DOI:10.1016/S2213-8587(24)00243-2. PMID:39541997. IF:41.800(Q1/1D).

Rojo-López, MI, Bermúdez-López, M, Castro, E, Farràs, C, Torres, G, Pamplona, R, Lecube, A, Valdivieso, JM, Fernández, E, Julve, J, Castelblanco, E, Alonso, N, Antentas, M, Barranco-Altirriba, M, Perera-Lluna, A, Franch-Nadal, J, Granado-Casas, M, Mauricio, D. Mediterranean Diet Is a Predictor of Progression of Subclinical Atherosclerosis in a Mediterranean Population: The ILERVAS Prospective Cohort Study. Nutrients. 2024; 16(21)DOI:10.3390/nu16213607. PMID:39519440. IF:5.000(Q1/2D).

Cheng, AYY, Mauricio, D, Ritzel, R, Al-Sofiani, ME, Bailey, T, Mabunay, MA, Bonnemaire, M, Melas-Melt, L, Mimouni, S, Davies, M. A post-hoc pooled analysis to evaluate efficacy and safety of insulin glargine 300 U/mL in insulin-naïve people with type 2 diabetes with/ without prior use of glucagon-like peptide-1 receptor agonist therapy. DIABETES RESEARCH AND CLINICAL PRACTICE. 2024; 217DOI:10.1016/j.diabres.2024.111871. PMID:39343145. IF:7.400(Q1/1D).

Facundo, AN, Magalhaes, M, Nascimento, GC, Azulay, RS, Santos, RM, Freitas, LA, Nascimento, AGPAC, Rodrigues, VP, Santos, WC, Beckman, AMGS, Abreu, JMF, Silva, RP, Carneiro, EL, Neto, CPO, da Costa, RMG, Corcoy, R, Mato, E, Faria, MS. The expression of VDACs and Bcl2 family genes in pituitary adenomas: clinical correlations and postsurgical outcomes. Frontiers in Endocrinology. 2024; 15DOI:10.3389/fendo.2024.1481050. PMID:39449743. IF:4.600(Q1/3D).

Genua, I, Sardà, H, Pérez, A. Cardiometabolic effects of weight loss. Atencion Primaria. 2024; 56(10)DOI:10.1016/j.aprim.2024.102953. PMID:38705132. IF:1.600(Q2/4D).

Pérez, A. GLP-1 receptor agonists in clinical practice. MEDICINA CLINICA. 2024; 163(5)DOI:10.1016/j.medcli.2024.02.018. PMID:38688736. IF:2.100(Q2/3D).

Somolinos-Simón, FJ, García-Sáez, G, Tapia-Galisteo, J, Corcoy, R, Hernando, ME. Cluster analysis of adult individuals with type 1 diabetes: Treatment pathways and complications over a five-year follow-up period. DIABETES RESEARCH AND CLINICAL PRACTICE. 2024; 215DOI:10.1016/j.diabres.2024.111803. PMID:39089589. IF:7.400(Q1/1D).

Cheng, A, Mauricio, D, Ritzel, R, Al-Sofiani, ME, Bailey, T, Mabunay, M, Bonnemaire, M, Lydie, MM, Mimouni, S, Davies, M. Efficacy and safety of insulin glargine 300 U/mL in insulin-naive people with type 2 diabetes with/without prior use of glucagon-like peptide-1 receptor agonist therapy. DIABETOLOGIA. 2024; 67DOI:. PMID:. IF:10.200(Q1/1D).

Claramunt, FC, Lazaro, D, Salter, J, Paldánius, P, Mauricio, D. Non-invasive near-infrared system for screening for diabetes: first results from the ANODE03 clinical investigation. DIABETOLOGIA. 2024; 67DOI:. PMID:. IF:10.200(Q1/1D).

Torre, ELM, Alarcón, PP, Rodríguez, MM, Serrallonga, NB, Palomar, JR, Iglesias, DM, Hoyas, CN, Servat, OS, Kyriakos, G, Bellas, LC, Pla, RC, Ramonde, TM, López, ML, Madorell, BS, Borrás, JG. Open-label, descriptive, sequential study in type 1 diabetes patients to evaluate the Mylife™-Dose app with ISCI and compare it to a hybrid continuous insulin infusion system (CamAPS): Dose Human Loop study. DIABETOLOGIA. 2024; 67DOI:. PMID:. IF:10.200(Q1/1D).